NASDAQ$NKTR
Nektar Therapeutics · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Nektar's financial performance for Q2 2024 was reported.
Nektar Therapeutics reported revenue of $23.5 million and a net loss of $52.4 million for the second quarter of 2024. The company's cash and investments are expected to support operations into the third quarter of 2026.
- Revenue for the second quarter of 2024 was $23.5 million, compared to $20.5 million in the second quarter of 2023.
- Net loss for the second quarter of 2024 was $52.4 million, or $0.25 loss per share, compared to a net loss of $51.1 million, or $0.27 loss per share in the second quarter of 2023.
- Cash and investments in marketable securities were $290.6 million as of June 30, 2024.
- Enrollment is on track for topline data in the first half of 2025 for atopic dermatitis and topline data in mid-2025 for alopecia areata.
Headline financials
Revenue & EPS history
Nektar · Revenue · Quarterly
$23.5M
Forward guidance
Nektar expects its cash and marketable securities to support strategic development activities and operations into the third quarter of 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+0.7%
Avg return
Earnings day
+1.5%
Avg return
5 days after
-3.8%
Avg return
30 days after
50%
32 / 64 earnings
Positive
+24.8%
Q3 2017
Best reaction
-27.4%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | -7.9% | -32.6% | |
| Q4 2025 | +4.0% | +4.0% | +10.1% | |
| Q3 2025 | +1.9% | +4.6% | +3.2% | |
| Q1 2025 | -4.1% | +16.1% | +8.1% | |
| Q4 2024 | -0.6% | +7.3% | -24.4% | |
| Q3 2024 | +0.7% | -5.8% | -26.6% | |
| Q2 2024 | -5.9% | -2.5% | -5.1% | |
| Q1 2024 | +7.3% | +7.9% | -23.2% | |
| Q4 2023 | +13.3% | +16.7% | +33.3% | |
| Q3 2023 | -5.6% | -15.1% | -3.8% | |
| Q2 2023 | -10.8% | -8.8% | -42.2% | |
| Q1 2023 | -2.6% | -5.2% | -22.1% | |
| Q4 2022 | +8.6% | +12.9% | -54.0% | |
| Q3 2022 | +3.6% | +4.1% | -16.2% | |
| Q2 2022 | +9.2% | +5.4% | -10.3% | |
| Q1 2022 | -6.7% | -17.0% | -22.1% | |
| Q4 2021 | +10.0% | +5.2% | -44.2% | |
| Q3 2021 | -21.0% | -18.8% | -36.4% | |
| Q2 2021 | +1.0% | -4.0% | +1.6% | |
| Q1 2021 | +7.6% | +3.3% | -8.3% | |
| Q4 2020 | -0.4% | +4.3% | -12.2% | |
| Q3 2020 | +2.7% | -0.8% | +2.5% | |
| Q2 2020 | +0.5% | -6.2% | -13.0% | |
| Q1 2020 | +6.3% | +11.3% | +14.0% | |
| Q4 2019 | -2.8% | -9.2% | -19.5% | |
| Q3 2019 | +0.9% | +13.2% | +10.3% | |
| Q2 2019 | -27.4% | -34.5% | -40.9% | |
| Q1 2019 | +10.5% | +1.7% | +2.9% | |
| Q4 2018 | -7.1% | -6.4% | -18.1% | |
| Q3 2018 | -2.1% | +2.5% | +2.5% | |
| Q2 2018 | +8.7% | +8.6% | +19.0% | |
| Q1 2018 | +2.1% | +7.2% | -30.4% | |
| Q4 2017 | +18.8% | +13.3% | +22.8% | |
| Q3 2017 | +24.8% | +33.9% | +125.8% | |
| Q2 2017 | -7.8% | -9.8% | +11.0% | |
| Q1 2017 | +5.8% | +9.9% | +4.1% | |
| Q4 2016 | +13.1% | +9.9% | +79.4% | |
| Q3 2016 | -1.1% | +5.1% | -0.6% | |
| Q2 2016 | +1.6% | +0.5% | +7.4% | |
| Q1 2016 | -12.3% | — | — | |
| Q4 2015 | -0.2% | — | — | |
| Q3 2015 | +4.3% | — | — | |
| Q2 2015 | -5.6% | — | — | |
| Q1 2015 | +13.3% | — | — | |
| Q4 2014 | -2.7% | — | — | |
| Q3 2014 | -1.8% | — | — | |
| Q2 2014 | +7.4% | — | — | |
| Q1 2014 | -2.9% | — | — | |
| Q4 2013 | -2.5% | — | — | |
| Q3 2013 | +15.8% | — | — | |
| Q2 2013 | +11.9% | — | — | |
| Q1 2013 | -4.1% | — | — | |
| Q4 2012 | +1.6% | — | — | |
| Q3 2012 | -14.1% | — | — | |
| Q2 2012 | +0.6% | — | — | |
| Q1 2012 | -1.0% | — | — | |
| Q4 2011 | +9.5% | — | — | |
| Q3 2011 | -1.5% | — | — | |
| Q2 2011 | -5.4% | — | — | |
| Q1 2011 | +3.6% | — | — | |
| Q4 2010 | -4.9% | — | — | |
| Q3 2010 | -4.8% | — | — | |
| Q2 2010 | -2.2% | — | — | |
| Q1 2010 | -10.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro